These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23035454)

  • 1. Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel.
    Zhang W; Zhang D; Tan J; Cong H
    J Nanosci Nanotechnol; 2012 Sep; 12(9):7211-4. PubMed ID: 23035454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
    He Z; Gao J; Wang Q; Liu M; Li Y; Li X; Tang H; Zheng J
    Oncol Rep; 2008 Aug; 20(2):325-32. PubMed ID: 18636193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
    Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
    Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics.
    Lay CL; Liu HQ; Tan HR; Liu Y
    Nanotechnology; 2010 Feb; 21(6):065101. PubMed ID: 20057024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].
    Yan XJ; Liang LZ; Zeng ZY; Fu LW; Shi Z
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):609-13. PubMed ID: 16202317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Controlled release of paclitaxel from microparticles containing PLLA and its anti-tumor activity on human ovarian carcinoma cell line].
    Yang Q; Kang YQ; Wang HJ; Yin GF; Fang K; Yang K
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):212-6. PubMed ID: 19462892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of single-wall carbon nanotube-paclitaxel-folic acid conjugate as an anti-cancer targeting agent.
    Tavakolifard S; Biazar E; Pourshamsian K; Moslemin MH
    Artif Cells Nanomed Biotechnol; 2016 Aug; 44(5):1247-53. PubMed ID: 25783856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
    Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
    Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
    Ho EA; Soo PL; Allen C; Piquette-Miller M
    J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
    Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA
    Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
    Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
    Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
    Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
    Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
    Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
    Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
    Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.
    Cui X; Sun Y; Shen M; Song K; Yin X; Di W; Duan Y
    ACS Appl Mater Interfaces; 2018 Mar; 10(9):7821-7831. PubMed ID: 29411964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
    Wang L; Jia E
    Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
    Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
    J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.